Met­sera shares ear­ly da­ta on an­ti-obe­si­ty amylin can­di­date

Met­sera, which is at­tempt­ing to make long-act­ing obe­si­ty and meta­bol­ic dis­ease med­i­cines, has shared its first clin­i­cal da­ta as a re­cent­ly mint­ed pub­lic com­pa­ny. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER